MedPath

Tagged News

BlossomHill Therapeutics Advances EGFR-Mutant NSCLC Treatment with First-in-Class OMNI-EGFR Inhibitor BH-30643

Targeted TherapyOncology
  • BlossomHill Therapeutics has dosed the first patient in expansion cohorts of the SOLARA Phase 1/2 trial evaluating BH-30643, a first-in-class OMNI-EGFR inhibitor for advanced EGFR-mutant non-small cell lung cancer.
  • BH-30643 demonstrates sub-nanomolar potency against classical and atypical EGFR mutations while maintaining activity against T790M and C797S resistance mutations that commonly limit current therapies.
  • The expansion cohorts will assess objective response rates across diverse EGFR mutation subtypes, including treatment-naive patients, following successful dose escalation that showed favorable pharmacokinetics and preliminary anti-tumor activity.
  • The drug's broad-spectrum approach aims to address multiple EGFR mutations with a single agent while sparing wildtype EGFR and HER2 inhibition for improved tolerability.

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT06706076RecruitingPhase 1
BlossomHill Therapeutics
Posted 1/9/2025

Molecular Testing and Targeted Therapies Transform Treatment Landscape for Pediatric Low-Grade Gliomas

Targeted TherapyPrecision Medicine
  • Comprehensive molecular testing using NGS panels and methylation profiling has become foundational for accurately diagnosing pediatric low-grade gliomas and identifying actionable mutations like BRAF alterations.
  • Targeted therapies including BRAF and MEK inhibitors are emerging as compelling alternatives to traditional chemotherapy, offering oral administration and better tolerability for children.
  • The treatment approach has evolved from cytotoxic chemotherapy to precision medicine strategies that balance tumor control with quality of life over the chronic, multi-year treatment course.
  • Molecular diagnostics typically return within 2-4 weeks for full results, with initial pathology and specific mutations like BRAF V600E detectable within one week through targeted immunohistochemistry stains.

University of Houston Develops First Spleen-Targeted Nanoparticle System for Lupus Treatment

Targeted Therapy
  • University of Houston biomedical engineer Tianfu Wu has received a $1 million Department of Defense Impact Award to develop a novel spleen-specific drug delivery system for lupus treatment.
  • The innovative system uses mannose-modified lipid nanoparticles to directly target immune cells in the spleen, including B cells, plasmacytoid dendritic cells, and macrophages that drive lupus pathogenesis.
  • This approach represents the first instance of a spleen-specific targeting system designed for lupus models, potentially offering more precise treatment with reduced systemic side effects.
  • The technology aims to modulate immune responses rather than employing broad immunosuppression, addressing current therapeutic limitations in lupus management.

Bayer Partners with Kumquat Biosciences in $1.3 Billion Deal to Develop KRAS G12D Inhibitor for Hard-to-Treat Cancers

Targeted Therapy
  • Bayer and Kumquat Biosciences announced an exclusive global license and collaboration worth up to $1.3 billion to develop a KRAS G12D inhibitor targeting pancreatic, colorectal, and lung cancers.
  • The KRAS G12D mutation is found in 37% of pancreatic ductal adenocarcinoma cases, 13% of colorectal cancers, and 4% of non-small cell lung cancers, yet lacks effective treatment options despite occurring in nearly 25% of human cancers.
  • Kumquat received FDA clearance for its investigational new drug in July 2025 and will complete Phase Ia studies, while Bayer handles subsequent development and commercialization activities.
  • The collaboration addresses a critical unmet medical need in pancreatic cancer, which has a five-year survival rate of less than 10% and is projected to see a 95.4% increase in new cases by 2050.

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559RecruitingPhase 1
Astellas Pharma Inc
Posted 6/8/2022

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706TerminatedPhase 1
Mirati Therapeutics Inc.
Posted 3/6/2023

Day One Biopharmaceuticals Reports 310% Revenue Surge for Pediatric Cancer Drug OJEMDA

Targeted Therapy
  • Day One Biopharmaceuticals reported OJEMDA net product revenue of $33.6 million in Q2 2025, representing a 310% year-over-year increase driven by expanding adoption among pediatric oncologists.
  • The company wrote more than 1,000 OJEMDA prescriptions during the quarter, marking a 15% sequential increase and 346% rise compared to the prior year period.
  • Management reaffirmed annual OJEMDA revenue guidance of $140-150 million for 2025 and confirmed sufficient cash reserves to fund operations without external financing.
  • Two pivotal trials for OJEMDA, FIREFLY-1 and FIREFLY-2, remain on track with key clinical data expected in late 2025 and early 2026.

Vitiligo Treatment Pipeline Shows Promise with JAK Inhibitors and Novel Immunotherapies in Phase 3 Trials

Monoclonal AntibodyTargeted Therapy
  • Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials.
  • AbbVie's Upadacitinib and Pfizer's Ritlecitinib have both advanced to Phase 3 trials, demonstrating promising repigmentation results in vitiligo patients.
  • Novel approaches include Clinuvel's Afamelanotide in Phase 3 trials and Amgen's AMG 714 anti-IL-15 monoclonal antibody in Phase 2 development.
  • The pipeline reflects a paradigm shift towards targeted therapies and personalized medicine approaches, offering new hope for patients with this challenging autoimmune condition.

CDSCO Panel Recommends Approval for Vorasidenib with Phase-III Waiver for IDH-Mutant Gliomas in India

Drug ApprovalOrphan DrugTargeted Therapy
  • India's CDSCO panel has recommended approval for vorasidenib tablets (10 mg and 40 mg) with a waiver from local Phase-III clinical trials for treating IDH-mutant gliomas.
  • The dual IDH1/IDH2 inhibitor is indicated for adult and pediatric patients aged 12 years and older with Grade 2 astrocytoma or oligodendroglioma harboring IDH mutations.
  • The committee acknowledged the unmet medical need for these indications in India and noted the drug's orphan status in other countries.
  • A Phase-IV clinical trial in Indian patients will be mandatory, with the protocol to be submitted within 3 months of approval.

Novel Nanoparticle Formulations Enhance Paclitaxel Delivery to Cancer Tumors

Targeted Therapy
  • University of Arizona researchers developed Paclitaxome, a new nanovesicle formulation of paclitaxel that outperformed standard chemotherapy drugs Taxol and Abraxane in mouse models of triple-negative breast cancer and advanced pancreatic cancer.
  • The formulation chemically attaches paclitaxel to sphingomyelin to create nanovesicles that improve tumor delivery, extend circulation time, and reduce accumulation in healthy tissues like the liver and spleen.
  • Indian researchers created fluorescent nanoparticles coated with transferrin that selectively target cancer cells overexpressing transferrin receptors, releasing over 90% of paclitaxel over two days while sparing normal cells.
  • Both platforms demonstrate the potential for improved drug delivery systems that could reduce chemotherapy side effects while enhancing therapeutic efficacy across multiple cancer types.

Terbium-161 Radioimmunotherapy Shows Superior Efficacy Against Ovarian Cancer Stem Cells in Preclinical Study

Targeted Therapy
  • A novel radioimmunotherapy using Terbium-161 (¹⁶¹Tb) successfully eliminated ovarian cancer stem cells in preclinical models, outperforming the current gold standard Lutetium-177.
  • The ¹⁶¹Tb-DOTA-chCE7 conjugate completely eradicated all detected ovarian cancer stem cells and their differentiated progeny in live animal models, effectively preventing tumor growth.
  • The superior efficacy stems from ¹⁶¹Tb's emission of short-range conversion and Auger electrons alongside beta particles, enabling highly localized energy deposition and irreparable DNA damage within cancer stem cells.
  • This breakthrough offers renewed hope for targeting therapy-resistant cancer stem cells that drive tumor relapse, metastasis, and treatment resistance in ovarian cancer patients.

UNLV Researchers Achieve 99% Pancreas-Specific mRNA Delivery Using Novel ENDO Nanoparticle Platform

Targeted Therapy
  • UNLV researchers developed ENDO (Endogenous Targeting Lipid Nanoparticles) that achieve 99% selectivity for pancreatic delivery of mRNA therapeutics via intravenous injection.
  • The breakthrough technology exploits Vitamin D receptors on pancreatic cell surfaces to route nanoparticles specifically to the pancreas, marking the first material capable of such precision.
  • This targeted delivery system could revolutionize treatment for diabetes and pancreatic cancer by enabling direct mRNA therapy to pancreatic cells while minimizing systemic side effects.
  • The platform shows potential for expansion to other difficult-to-reach organs including the brain and heart, with commercialization efforts already underway through UNLV's Office of Economic Development.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.